Curis Raises $8.5M at $0.51, Slashes Warrant Strikes to $0.60
CRIS is trading near its 52-week low of $0.465 (15% above the low) on elevated volume (2.3× avg).
Summary
Curis priced an $8.5M private placement at a combined $0.51 per share, a discount to the $0.5333 last sale, with 16.7M shares and matching common warrants struck at $0.60, sold at-the-market to existing healthcare focused institutional investors. The company also repriced its January 2026 warrants from $15.00 and August 2026 warrants from $1.75 down to $0.60, wiping out most of the strike value on roughly 4.9M existing warrants. This follows the $5.6M public offering priced August 13 at $1.50 and the 10-Q's going-concern warning with cash runway only into Q4 2026. The raise is highly dilutive for a sub-$2M market cap and the warrant repricing signals the prior terms were unreachable. Proceeds are expected to fund operations only through initial CLL data in 5-10 patients in December 2026, so another raise is likely soon after.
Updates
· SEC 8-K — Common warrants for 16,666,680 shares are exercisable at $0.60 starting six months after issuance and expire April 19, 2032; placement agents receive a 6.5% cash fee.
At the time of this announcement, CRIS was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.47 to $33.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.